Skip to search formSkip to main contentSkip to account menu

annamycin

Known as: 2'-iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin, 5,12-naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-l-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)- 
A lipophilic, anthracycline antineoplastic antibiotic. Annamycin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Additional positive interim safety and efficacy data were reported for annamycin in the treatment of patients with relapsed or… 
2000
2000
Abstract : We studied the toxicity and antitumor activity of Liposomal/Annamycin in patients with metastatic breast carcinoma… 
1997
1997
Abstract : Annamycin is a non-cross resistant doxorubicin analog that is formulated in a liposomal carrier. We have completed a…